RT Journal Article
T1 Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.
A1 Puig-Domingo, Manuel
A1 Soto, Alfonso
A1 Venegas, Eva
A1 Vilchez, Ricardo
A1 Blanco, Concepción
A1 Cordido, Fernando
A1 Lucas, Tomás
A1 Marazuela, Mónica
A1 Casany, Rosa
A1 Cuatrecasas, Guillem
A1 Fajardo, Carmen
A1 Gálvez, María Ángeles
A1 Maraver, Silvia
A1 Martín, Tomás
A1 Romero, Enrique
A1 Paja, Miguel
A1 Picó, Antonio
A1 Bernabeu, Ignacio
A1 Resmini, Eugenia
A1 ACROCOMB study group, 
K1 Acromegalia
K1 Acromegaly
K1 Análogos de la somatostatina
K1 Cabergolina
K1 Cabergoline
K1 IGF-I
K1 Lanreotida
K1 Lanreotide
K1 Pegvisomant
K1 Somatostatin analogues
AB To describe real-world use of lanreotide combination therapy for acromegaly. ACROCOMB is a retrospective observational Spanish study of patients with active acromegaly treated with lanreotide combination therapy between 2006 and 2011. 108 patients treated at 44 Spanish Endocrinology Departments were analyzed separately: 61 patients received lanreotide/cabergoline (cabergoline cohort) and 47 lanreotide/pegvisomant (pegvisomant cohort). Patient median age was 50.8 years in the cabergoline cohort and 42.7 years in the pegvisomant cohort. Prior medical treatments were somatostatin analogue (SSA) monotherapy (40 [66%] patients) or dopamine agonists (7 [11%] patients) in the cabergoline cohort and SSA (29 [62%] patients) or pegvisomant monotherapy (16 [34%] patients) in the pegvisomant cohort. Across both cohorts 12 patients were previously untreated, and prior therapy was unknown/missing in 4 patients. Median duration of combined treatment was 1.6 years (0.1-6) and 2.1 years (0.4-6.3) in the cabergoline and pegvisomant cohorts, respectively. At baseline, median insulin growth factor (IGF)-I values were 149% upper limit of normal (ULN) (15-505%) in the cabergoline cohort and 156% ULN (15-534%) in the pegvisomant cohort, and decreased to 104% ULN (13-557%) p In clinical practice lanreotide treatment combinations are useful options for patients with acromegaly when monotherapy is insufficient; particularly, the combination of lanreotide and pegvisomant in patients not controlled with either SSA or pegvisomant alone has high efficacy and is well-tolerated.
YR 2016
FD 2016-07-20
LK http://hdl.handle.net/10668/10301
UL http://hdl.handle.net/10668/10301
LA en
LA es
DS RISalud
RD Apr 18, 2025